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Summary
Germ-line and somatic truncating mutations of the APC
gene are thought to initiate colorectal tumor formation
in familial adenomatous polyposis syndrome and spo-
radic colorectal carcinogenesis, respectively. Recently,
an isoleucinerlysine polymorphism at codon 1307
(I1307K) of the APC gene has been identified in 6%–7%
of the Ashkenazi Jewish population. To assess the risk
of this common APC allelic variant in colorectal carci-
nogenesis, we have analyzed a large cohort of unselected
Ashkenazi Jewish subjects with adenomatous polyps
and.or colorectal cancer, for the APC I1307K polymor-
phism. The APC I1307K allele was identified in 48
(10.1%) of 476 patients. Compared with the frequency
in two separate population control groups, the APC
I1307K allele is associated with an estimated relative risk
of 1.5–1.7 for colorectal neoplasia (both ). Fur-P  .01
thermore, compared with noncarriers, APC I1307K car-
riers had increased numbers of adenomas and colorectal
cancers per patient ( ), as well as a younger ageP  .03
at diagnosis. We conclude that the APC I1307K variant
leads to increased adenoma formation and directly con-
tributes to 3%–4% of all Ashkenazi Jewish colorectal
cancer. The estimated relative risk for carriers may jus-
tify specific clinical screening for the 360,000 Americans
expected to harbor this allele, and genetic testing in the
setting of long-term–outcome studies may impact sig-
nificantly on colorectal cancer prevention in this
population.
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Introduction
Approximately 15%–20% of colorectal cancer (CRC),
the second leading cause of cancer death in North Amer-
ica, occurs in familial aggregations (Cannon-Albright et
al. 1988; Landis et al. 1998). Familial adenomatous
polyposis (FAP), caused by an inherited functional mu-
tation of one copy of the adenomatous polyposis coli
gene (APC [MIM 175100]) is thought to account for
!1% of all CRC (Kinzler and Vogelstein 1996). Germ-
line mutation of a DNA mismatch-repair gene, causing
hereditary nonpolyposis colorectal cancer (HNPCC), is
believed to be responsible for ∼2% of CRC (Aaltonen
et al. 1998). The majority of the remaining hereditary
CRC is unexplained. It is plausible that relatively com-
mon but less penetrant alleles may account for a signif-
icant proportion of inherited or even seemingly sporadic
CRC. The isoleucinerlysine polymorphism at codon
1307 of the APC gene (APC I1307K) recently has been
reported to be carried by 6.1% of New York Ashkenazi
Jewish individuals (Laken et al. 1997) and 7.0% of
Washington, DC, Ashkenazim (Woodage et al. 1998).
In contrast with these control populations, the carrier
frequency of this allele was significantly elevated, to
28%, in 28 Ashkenazi persons with a personal and fam-
ily history of CRC (Laken et al. 1997). Bayesian analysis
of genetic linkage in these families confirmed this in-
creased risk of CRC (Peterson et al. 1998).
Mechanistically, the sequence encoded by the APC
I1307K polymorphism is hypermutable compared with
wild-type APC sequence (Laken et al. 1997; Gryfe et al.
1998). This mutational susceptibility leads to somatic
biallelic inactivation of the APC gene and to colorectal
tumorigenesis (Gryfe et al. 1998). Despite APC I1307K
encoding a polyadenine nucleotide repeat, hypermuta-
bility of this sequence was not accounted for by tumor
microsatellite instability (Gryfe et al. 1998). Although
previous findings clearly support the somatic hyper-
mutability of the APC I1307K genomic sequence, subtle
functional impairment of the APC I1307K gene product
cannot be excluded.
The actual risk of APC I1307K for colorectal neo-
plasia remains controversial. When data from patients
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with a family history of CRC were combined with data
from additional individuals not ascertained by family
history, a 10.4% APC I1307K carrier frequency among
211 patients with CRC was observed (Laken et al.
1997). These findings support a modest odds ratio (OR)
of 1.8 (95% confidence interval [95%CI] 1.05–2.8;
) for subjects with colorectal neoplasia, com-P  .03
pared with controls. A similar but statistically insignif-
icant risk estimate for CRC (OR 1.9; 95%CI 0.84–4.2)
was observed among 55 individuals with CRC and
5,026 unaffected controls (Woodage et al. 1998). The
APC I1307K polymorphism was originally identified in
an individual with eight colorectal adenomatous polyps
(Laken et al. 1997). More recently, the polymorphism
was found to be carried by three (38%) of eight British
Ashkenazi Jews with multiple adenomas (Frayling et al.
1998). However, to date there has been no large-scale
systematic study of the phenotypic effects of the APC
I1307K allele. Thus, the relative risk of APC I1307K
for colorectal polyposis and cancer remains incompletely
understood, but it is of great importance to the 1360,000
American Ashkenazi Jews estimated to carry this allele.
To elucidate the attributable risk and phenotypic ef-
fects of the APC I1307K polymorphism, we have eval-
uated a large cohort of unselected Ashkenazi Jewish pa-
tients with either CRC or adenomatous polyps. TheAPC
I1307K variant was present in a significantly increased
proportion of this colorectal-tumor population, com-
pared with that in controls, and carriers were observed
to have significantly elevated numbers of malignant and
premalignant colorectal neoplasms, compared to non-
carriers. These findings support a significant biological
role for this allele in CRC predisposition.
Subjects and Methods
Cohort and Phenotypic Data
Subjects were identified by searching Mount Sinai
Hospital records for Jewish patients who had been ad-
mitted for surgery during 1977–97 and who had a di-
agnosis of colorectal adenocarcinoma and/or adenoma-
tous polyps. Additionally, a case series of Jewish patients
with either pancreatic and ampullary adenocarcinoma
who previously had been analyzed for the BRCA2 mu-
tation (Ozcelik et al. 1997) were further investigated for
the current study. It is estimated that 190% of Jews from
the greater Toronto area are of Ashkenazi origin (J.
Brodbar [Jewish Federation of Greater Toronto, United
Jewish Appeal Canada], personal communication). All
pathology specimens for each subject were reviewed, and
a database was prepared with patient- and pathology-
phenotypic features. Individuals with FAP were excluded
from analysis, and patients with underlying inflamma-
tory bowel disease were analyzed separately. Because
accurate and consistent assessment of family cancer his-
tories could not be ensured by retrospective chart review
of this cohort, no attempt was made to obtain this
information.
Representative normal and tumor tissues from each
individual were identified from paraffin-embedded sur-
gical pathology samples, and unstained and hematox-
ylin- and eosin-stained sections were prepared for DNA
analysis. In accordance with genetic-testing research
guidelines (Clayton et al. 1995) and institutional ap-
proval, these samples were stripped of identifiers and
were coded to anonymously link them to the phenotypic
database prepared prior to blinded genetic testing. Pa-
tients with the same surname were given consecutive
DNA-sample numbers, to indicate that they might be
related. Normal genomic DNA was isolated from mi-
crodissected paraffin-embedded tissues, by standard pro-
teinase K digestion (Jen et al. 1994).
APC I1307K Germ-Line Analysis
Codons 1303–1317 of the APC gene were amplified
by PCR, from normal genomic DNA template, with the
following primers: forward, 5′-AGATTCTGCTAA-
TACCCTGC-3′; and reverse, 5′-GAACTTCGCTCA-
CAGGATC-3′. Single-strand conformation polymor-
phism (SSCP) analysis of the denatured 83-bp PCR
product was performed by means of 9–10-W electro-
phoretic separation on an 8% polyacrylamide gel with
5% glycerol, at 4C for 16 h. All positive samples were
confirmed by dideoxy chain-termination reaction
ThermoSequenase (Amersham) sequencing of an inde-
pendent PCR amplification product from a newly pre-
pared second genomic DNA sample from the same case.
Given the unlinked nature of the samples, neither car-
riers nor noncarriers were notified of the test results.
Statistical Methods
APC I1307K carrier rates in patients with colorectal
tumor and in control populations were compared by
either x2 or Fisher’s exact test, as were other categorical
factors (i.e., gender and anatomical site of CRC) in APC
I1307K carrier and noncarrier patients with colorectal
tumor. APC I1307K carrier and noncarrier continuous
variables (i.e., colorectal and extracolonic tumor number
per patient and age at diagnosis) were compared by Stu-
dent’s t-test, with Welch’s correction for unequal vari-
ances when appropriate. Carrier and noncarrier cumu-
lative colorectal-tumor distributions by age at diagnosis
were estimated by the Kaplan-Meier method and were
compared by the log-rank test.
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Table 1
APC I1307K Carrier Rates
CATEGORY
NO. (%)
I1307K
Carriers Total
Patients with CRC 41 (10.1) 404
Patients with adenoma 7 (9.7) 72
Total 48 (10.1) 476
Figure 1 a, SSCP analysis of APC codons 1303–1317. Lanes N,
PCR product from patients without APC alteration. Lane C, PCR
product from a carrier of the APC I1307K alteration. The arrowhead
points to the APC I1307K band with altered electrophoretic mobility.
b, Reverse-primer sequence of APC of germ-line tissue from an APC
I1307K carrier. The arrowhead points to the polymorphic TrA
substitution.
Results
We identified 3,535 patients who had undergone sur-
gical resection for either CRC or adenoma, and, in their
admitting record, 491 (13.9%) of these individuals in-
dicated that they were Jewish. Blocks were retrieved, and
amplifiable DNA was obtained in 476 (96.9%) of these
491 cases (fig. 1). The APC I1307K polymorphism was
detected in the germ line of 48 (10.1%) of these 476
patients (table 1). The frequency of this APC allelic var-
iant was similar in both the patients with cancer and the
patients with only adenoma. Although no CRC family-
history data was available, none of the 48 APC I1307K
carriers had redundant surnames.
APC I1307K-carrier demographic features and tumor
phenotype were compared with those of noncarriers (ta-
ble 2). No significant difference was found in either pa-
tient gender or anatomic location of CRC. Mean age at
CRC diagnosis was ∼2 years younger in APC I1307K
carriers than in noncarriers ( ). Comparison ofP  .13
the cumulative distribution curves (fig. 2) revealed a sig-
nificantly younger age at tumor diagnosis in APC
I1307K carriers compared with noncarriers (hazard ra-
tio 1.45; 95%CI 1.09–2.21; ).P  .01
Analysis of tumor numbers revealed striking differ-
ences between APC I1307K carriers and noncarriers (ta-
ble 2). The 48 APC I1307K carriers were found to have
139 colorectal cancers and adenomatous polyps, com-
pared with 835 colorectal neoplasms identified in 428
noncarriers. In terms of OR, this corresponds to a rel-
ative-risk estimate of 1.48 (95%CI 1.05–2.10; )P  .03
for colorectal neoplasia in APC I1307K carriers. Fur-
thermore, theAPC I1307K carrier rate steadily increased
with colorectal neoplasm number (fig. 3; for the trend,
). Of the four patients with 110 colonic neo-P  .001
plasms, two were found to be APC I1307K carriers. In
contrast to FAP, no microscopic adenomas were iden-
tified in routine histologic sections of flat mucosa from
any of the APC I1307K carriers.
APC I1307K carriers were no more likely to have
extracolonic cancers than were noncarriers (table 2). The
only extracolonic cancers present in carriers were one
breast cancer and one bladder cancer, and these were
also present, at a similar frequency, in noncarriers (seven
breast cancers and eight bladder cancers). All other ex-
tracolonic cancers in the noncarriers were present at fre-
quencies !1%.
To assess the contribution of APC I1307K to colitis-
associated neoplasia and pancreatic and ampullary car-
cinomas, we separately analyzed Ashkenazi Jewish in-
dividuals affected by these conditions. Of seven patients
with underlying inflammatory bowel disease and either
CRC or adenoma/dysplasia, none were found to be APC
I1307K carriers. Two (5.7%) of 35 patients with pan-
creatic cancer and 0 of 6 patients with ampullary cancer
were identified as being APC I1307K carriers.
Discussion
Our study provides several lines of evidence that APC
I1307K is associated with a modest but clinically sig-
nificant increase in the risk of CRC. The 10.1% APC
I1307K carrier frequency observed in our unselected pa-
tients with either CRC or adenoma is significantly ele-
vated compared with the previously published 6.1% (47/
766) carrier rate in non-CRC Ashkenazi Jewish controls
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Table 2
APC I1307K Carrier and Tumor Phenotype
NO. (%) OF INDIVIDUALS
I1307K Non-I1307K
Gender:
Male 26 (54) 239 (56)
Female 22 (46) 189 (44)
CRC site:
Right 13 (28) 141 (36)
Left 20 (43) 149 (38)
Rectum 14 (30) 101 (26)
Mean age of patients  SE (years) 70.2  1.2 72.2  .5
Tumor types (per patient  SE):
CRCs .98  .42 .91  .02
Adenomasa 1.92  .08 1.04  .08
Totala 2.90  .42 1.95  .08
Extracolonic cancers 2 (4.2) 32 (7.5)
a There was a significant difference betweenAPC I1307K carriers
and noncarriers ( ).P ! .05
Figure 2 Cumulative distribution of time until colorectal-tumor
diagnosis, for APC I1307K carriers () and noncarriers (). The time
until colorectal-tumor diagnosis inAPC I1307K carriers is significantly
shifted to a younger age, compared with that in noncarriers (P 
)..01
ascertained through a New York Tay-Sachs screening
program ( ; Laken et al. 1997). On the basis ofP  .01
the OR, the estimated relative risk for colorectal neo-
plasia in APC I1307K carriers is 1.72 (95%CI
1.13–2.61). Recently, a Washington, DC, series, which
included both unaffected individuals and those with a
variety of cancers, demonstrated an APC I1307K carrier
rate of 7.0% (326/4,635 [Woodage et al. 1998]). Com-
pared with this control estimate, our observed rate of
APC I1307K in patients with colorectal tumor is sig-
nificantly elevated, to a similar degree (OR 1.48; 95%CI
1.08–2.04; ). Furthermore, because the APCP  .01
I1307K polymorphism predisposes to adenoma forma-
tion that is often asymptomatic, the carrier rate in con-
trol populations may overestimate the true unaffected-
carrier rate—and thus lead to an underestimate of the
risk of APC I1307K for colorectal neoplasia.
Testing of a large Toronto control group to establish
the local carrier rate of APC I1307K was not possible
for the current study. However, results of previous stud-
ies of founder mutations in North American Ashkenazi
populations make feasible the comparison of our To-
ronto APC I1307K data with data on previously pub-
lished controls. First, no significant difference was
observed in APC I1307K control carrier frequencies de-
rived from the large New York and Washington, DC,
studies (Laken et al. 1997; Woodage et al. 1998). Sec-
ond, previous studies have revealed that the rates of three
founder mutations of the hexosaminidase gene were sim-
ilar in five urban American and Canadian Ashkenazi
populations, including that of Toronto (Fernandes et al.
1992). Third, the rates of three BRCA1 and BRCA2
founder mutations have been observed to be similar in
different American Ashkenazi control populations (Roa
et al. 1996; Oddoux et al. 1996; Struewing et al. 1997).
Presumably, carrier rates of all these allelic variants are
similar in various urban centers because they arose in
Ashkenazi ancestors long ago and were not significantly
influenced by later migration to North America.
Our OR estimate of 1.72 is slightly lower than pre-
vious risk estimates of the APC I1307K allele but is
supported by both a tighter confidence interval and
more-powerful statistical association. The number of pa-
tients with colorectal tumors who were included in the
present study is more than double that in previous stud-
ies, and the inclusion of only unselected cases avoids the
potential biases of family-history selection (Laken et al.
1997) and volunteers (Woodage et al. 1998) that are
present in previous APC I1307K CRC analyses. Our
10.1% carrier frequency is significantly lower than either
the 28% rate observed in individuals with a personal
and family history of CRC ( ; Laken et al. 1997)P  .02
or the 38% rate observed in persons with multiple ad-
enomas ( ; Frayling 1998). However, both theseP  .04
selected populations were very small and may have been
influenced by other environmental or genetic modifiers.
Two additional independent findings support a pre-
disposition to colorectal neoplasia in APC I1307K car-
riers. First, cumulative colorectal-tumor distribution by
age at diagnosis was significantly shifted to a younger
age in carriers, compared with that in noncarriers. Al-
though this effect was small in terms of absolute mean
age at diagnosis, it supports a definite biological effect
and is in agreement with previous findings (Laken et al.
1997). Second, carriers were found to have an increase
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Figure 3 APC I1307K carrier rate and number of colorectal
neoplasms. A significant correlation between APC I1307K carrier fre-
quency and an increasing number of colorectal neoplasms is observable
( ).P  .001
in the number of colorectal neoplasms, with an estimated
relative risk of 1.48. This value closely parallels the rel-
ative risk predicted from carrier-rate data and introduces
a novel and potentially powerful method to indepen-
dently quantify risk of colorectal-tumor initiation
from low-penetrant exposures (either genetic or envi-
ronmental).
If it is assumed that CRC risk in the Ashkenazi Jewish
population is the same as that in the general American
population, then the estimated relative risks suggest that
the lifetime risk that APC I1307K carriers will develop
CRC is ∼9%–10% (Landis et al. 1998). Although these
relative-risk estimates are consistent with a low-pene-
trant predisposition allele, there is a significant associ-
ated clinical effect due to the common occurrence of this
allele in the population. In fact, both our carrier fre-
quency and our previously published allele-specific so-
matic mutation rate (Gryfe et al. 1998) suggest that
3%–4% of all Ashkenazi Jewish colorectal neoplasia
may be directly attributable to APC I1307K. Thus, al-
though lifetime risks to the individual carrier are only
9%–10%, this likely represents a more significant con-
tribution to the overall burden of colorectal neoplasia
in this population than is imparted by FAP and HNPCC
combined. However, one consequence of the relatively
low penetrance of the APC I1307K allele predicted from
the present study is that analyses of allele frequency in
probands not ascertained for CRC—such as those anal-
yses that recently have been published (Petrukhin et
al. 1997; Abrahamson et al. 1998; Woodage et al.
1998)—are unlikely to detect a significant association
with a positive family history of CRC, unless very large
numbers of individuals are tested.
The overrepresentation of carriers in the subgroup of
individuals with multiple colorectal neoplasms is partic-
ularly interesting from a clinical viewpoint. Overall,
there were 59 patients with four or more colorectal ne-
oplasms, who represented 12% of the total cohort, and
13 (22%) of these 59 were APC I1307K carriers. Of the
four patients with 10 colorectal neoplasms (range
10–19), two were found to be APC I1307K carriers.
Attenuated adenomatous polyposis coli (AAPC) has pre-
viously been characterized by both increased adenoma
formation (range 10–99) and nonsense germ-line mu-
tations at the extreme 5′ and 3′ ends of the APC gene
(Spirio et al. 1993; van der Luijt et al. 1996). Our find-
ings suggest that, in addition to these previously ob-
served AAPC mutations, other mechanisms may con-
tribute to the appearance of multiple adenomas. We
predict that a significant fraction of patients with mul-
tiple polyps may have an important inherited predis-
position due to either less-penetrant APC alterations or
other modifier genes. Results of our study indicate that
careful examination of the pathological phenotype may
be a powerful method to accurately identify these pa-
tients and characterize the contribution from their in-
herited predisposition.
Using several independent lines of evidence, we have
demonstrated relative-risk estimates of ∼1.5–1.7 for co-
lorectal neoplasia in APC I1307K carriers. These results
raise important public-health issues regarding clinical
screening and genetic-testing recommendations. Our risk
estimates are similar to those that have been calculated
for persons with a family history of either CRC or
adenoma in a first-degree relative (Fuchs et al. 1994;
Winawer et al. 1996), for whom the American Gas-
troenterology Association (AGA) has advocated more-
stringent clinical screening (Winawer et al. 1997). The
CRC age-at-diagnosis data from the present study (fig.
2) suggest that standard AGA clinical screening begin-
ning at age 50 years (Winawer et al. 1997) is likely to
be effective for APC I1307K carriers who do not have
a significant family history but who do have a modestly
increased risk for development of CRC. However, in
view of previous findings in individuals with a family
history of either CRC or adenomatous polyps (Laken et
al. 1997), more-rigorous clinical screening beginning at
a younger age should be recommended to APC I1307K
carriers who have a significant family history.
Genetic testing for the APC I1307K polymorphism in
the Ashkenazi Jewish population is a more contentious
issue and of great importance to the 360,000 predicted
carriers in the United States. Issues surrounding positive
genetic tests—such as potential negative psychological
effects and difficulties in obtaining insurance—have led
the American Society of Clinical Oncology (ASCO) to
support genetic testing for cancer predisposition only in
the setting of a strong family history (American Society
of Clinical Oncology 1996). Such histories are likely to
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be absent, with the lower penetrance of APC I1307K.
Furthermore, neither a positive nor a negative genetic
result for this allele is likely to have an impact on clinical
screening recommendations in individuals with a strong
family history. However, several additional factors must
be considered before recommendations regarding testing
for the APC I1307K allele are made. First, CRC is a
common and often fatal disease that is potentially pre-
ventable by endoscopic screening. Second, 180% of
CRC occurs in the absence of a family history for this
disease (Cannon-Albright et al. 1988). Third, in accor-
dance with ASCO guidelines (American Society of Clin-
ical Oncology 1996), APC I1307K testing is easily in-
terpreted, and positive test results are likely to influence
medical management in the majority of individuals. De-
spite both the common occurrence of CRC and the ef-
fectiveness of colonoscopy, screening compliance re-
mains poor (Centers for Disease Control and Prevention
1996). However, individuals without a family history of
CRC who are aware of their APC I1307K carrier status
and who are at modestly increased risk for development
of CRC may be more motivated to undergo colonos-
copic screening. Our data indicate that genetic testing
of Ashkenazi Jews with or without a family history of
CRC, followed by appropriate clinical screening, might
significantly benefit the 9%–10% of carriers expected to
develop CRC. Similarly, screening of these individuals
could potentially lead to either the prevention or early
diagnosis of ∼10% of all Askenazi Jewish CRC. Because
the full impact of genetic testing on this population is
not currently known, it should only be conducted in
conjunction with pre- and posttest genetic counseling
and in the setting of long-term–outcome research stud-
ies. Further studies will be required to accurately deter-
mine how family history and other genetic and environ-
mental factors could influence neoplasia risks in APC
I1307K carriers.
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